ELDN
Eledon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.82
−7.34%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +1.6%
- EBIT
- +3.8%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +17.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- -27.9%
- EBIT
- -18.0%
- Net income
- -26.1%
- EPS
- +25.3%
- Free cash flow
- -31.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026